Actively Recruiting
A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
Led by JIANG LONGWEI · Updated on 2025-02-12
1
Participants Needed
2
Research Sites
56 weeks
Total Duration
On this page
Sponsors
J
JIANG LONGWEI
Lead Sponsor
C
China Pharmaceutical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Albumin-bound Paclitaxel/Granulocyte drug can treat patients with recurrent/metastatic breast cancer. The main questions it aims to answer are: To verify the safety of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer. To evaluate the efficacy of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer. To detect the pharmacokinetic behavior of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer.
CONDITIONS
Official Title
A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female, aged 18 years or older
- Signed informed consent form
- Diagnosed with recurrent or metastatic advanced breast cancer according to TNM standards
- Have received standard first-line treatments
- Expected survival time of 3 months or more
- ECOG score of 2 or less and KPS of 70 points or higher
- Liver, kidney, and bone marrow functions are essentially normal
- Women of childbearing age must use effective contraception before enrollment and for 3 months after treatment
You will not qualify if you...
- Received other anti-tumor treatments within 4 weeks before enrollment
- History of allergy to paclitaxel, albumin naproxen, ibuprofen, trimethoprim, or ampicillin
- Positive blood pregnancy test
- Require anticoagulant therapy
- Have active infectious diseases
- History of bone marrow or organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Jinling Hospital
Nanjing, Jiangsu, China, 210002
Actively Recruiting
2
Jinling Hospital
Nanjing, Jiangsu, China, 210002
Actively Recruiting
Research Team
J
Jiang Longwei, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here